Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (181-190 of 337) with videos related to

Pageof 34
Sort By:
Arthritis and Rheumatism|June 4, 2005
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity geneAnne Hinks, Anne Barton, Sally John, et al.
European Journal of Dermatology : EJD|August 4, 2007
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasisKristian Reich, Frank O Nestle, Ying Wu, et al.
The Journal of Investigative Dermatology|November 24, 2007
Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohortRhodri L L Smith, Richard B Warren, Steve Eyre, et al.
International Journal of Behavioral Medicine|October 23, 2015
Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?Chris Keyworth, Pauline A Nelson, Carolyn A Chew-Graham, et al.
Lancet (London, England)|October 18, 2005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialKristian Reich, Frank O Nestle, Kim Papp, et al.
JAMA Dermatology|July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisZenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.
Dermatology and Therapy|February 23, 2022
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisAndrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Effectiveness of Subcutaneous Methotrexate in Chronic Plaque PsoriasisPaul Devakar Yesudian, Joyce Leman, Periasamy Balasubramaniam, et al.
Pageof 34

Showing results (181-190 of 337) with videos related to

Sort By:
Pageof 34
Arthritis and Rheumatism|June 4, 2005
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity geneAnne Hinks, Anne Barton, Sally John, et al.
European Journal of Dermatology : EJD|August 4, 2007
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasisKristian Reich, Frank O Nestle, Ying Wu, et al.
The Journal of Investigative Dermatology|November 24, 2007
Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohortRhodri L L Smith, Richard B Warren, Steve Eyre, et al.
International Journal of Behavioral Medicine|October 23, 2015
Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?Chris Keyworth, Pauline A Nelson, Carolyn A Chew-Graham, et al.
Lancet (London, England)|October 18, 2005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialKristian Reich, Frank O Nestle, Kim Papp, et al.
JAMA Dermatology|July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisZenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.
Dermatology and Therapy|February 23, 2022
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisAndrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Effectiveness of Subcutaneous Methotrexate in Chronic Plaque PsoriasisPaul Devakar Yesudian, Joyce Leman, Periasamy Balasubramaniam, et al.
Pageof 34